Provided by Tiger Trade Technology Pte. Ltd.

Monte Rosa Therapeutics

14.32
+0.06000.42%
Post-market: 14.320.00000.00%16:10 EDT
Volume:1.06M
Turnover:15.09M
Market Cap:1.22B
PE:-8.21
High:14.34
Open:14.21
Low:13.83
Close:14.26
52wk High:25.77
52wk Low:4.80
Shares:85.31M
Float Shares:54.48M
Volume Ratio:0.99
T/O Rate:1.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7450
EPS(LYR):-0.4650
ROE:-42.66%
ROA:-21.63%
PB:2.51
PE(LYR):-30.80

Loading ...

Monte Rosa Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
May 12

Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX) and Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
May 08

Monte Rosa Therapeutics reports Q1 revenue $4.21M, consensus $11.39M

TIPRANKS
·
May 08

Monte Rosa Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Monte Rosa Therapeutics Q1 collaboration revenue drops 95%

Reuters
·
May 07

Monte Rosa publishes investor presentation on molecular glue degrader pipeline and Phase 2 plans

Reuters
·
May 07

Monte Rosa Q1 FY26 net loss widens to $44.5 million; revenue falls to $4.2 million

Reuters
·
May 07

BRIEF-Monte Rosa Therapeutics Q1 Net Income USD -44.503 Million

Reuters
·
May 07

Monte Rosa Therapeutics Q1 Operating Expenses USD 54.244 Million

THOMSON REUTERS
·
May 07

Monte Rosa Therapeutics Q1 Operating Income USD -50.034 Million

THOMSON REUTERS
·
May 07

Press Release: Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Dow Jones
·
May 07

Monte Rosa CEO Markus Warmuth sells 5,467 shares for $103,443.57

Reuters
·
May 06

Monte Rosa grants inducement awards: options for 38,925 shares at $18.8 exercise price

Reuters
·
May 06

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 06

Monte Rosa Therapeutics announces annual shareholder meeting

Reuters
·
Apr 30

What You Need To Know About The Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Analyst Downgrade Today

Simply Wall St.
·
Apr 21

Monte Rosa Therapeutics to present preclinical data on MRT-55811

TIPRANKS
·
Apr 20

Monte Rosa presents CCNE1 degrader data at AACR meeting

Reuters
·
Apr 20

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors

GlobeNewswire
·
Apr 20

Top Executive’s Surprise Move Shakes Up Monte Rosa Therapeutics Insider Activity

TIPRANKS
·
Apr 16